Antibody Mimetics, Peptides, and Peptidomimetics
In spite of their widespread applications as therapeutic, diagnostic, and detection agents, the limitations of polyclonal and monoclonal antibodies have enthused scientists to plan for next-generation biomedical agents, the so-called antibody mimetics, which offer many advantages compared to traditional antibodies. Antibody mimetics could be designed through protein-directed evolution or fusion of complementarity-determining regions with intervening framework regions. In the recent decade, extensive progress has been made in exploiting human, butterfly (Pieris brassicae), and bacterial systems to design and select mimetics using display technologies. Notably, some of the mimetics have made their way to market. Numerous limitations lie ahead in developing mimetics for different biomedical usage, particularly for which conventional antibodies are ineffective. This chapter presents a brief overview of the current characteristics, construction, and applications of antibody mimetics.
Key wordsAntibody mimetics Protein engineering Monoclonal antibodies (mAbs) Therapeutics Diagnostics
This work has been supported by China Nature Science Foundation (grant no. 31572556), Ph.D. Programs Foundation of Ministry of Education (grant no. 20130204110023), and The Key Construction Program (grant no. 2015SD0018) of International Cooperation Base in S&T, Shaanxi Province, China.
- 8.Russell WMS, Burch RL, Hume CW (1959) The principles of humane experimental technique. Methuen & Co., LondonGoogle Scholar
- 10.Schönfeld D, Matschiner G, Chatwell L, Trentmann S, Gille H, Hülsmeyer M, Brown N, Kaye PM, Schlehuber S, Hohlbaum AM, Skerra A (2009) An engineered lipocalin specific for CTLA-4 reveals a combining site with structural and conformational features similar to antibodies. Proc Natl Acad Sci 106:8198–8203CrossRefPubMedPubMedCentralGoogle Scholar
- 13.Ahlgren S, Wållberg H, Tran TA, Widström C, Hjertman M, Abrahmsén L, Berndorff D, Dinkelborg LM, Cyr JE, Feldwisch J, Orlova A (2009) Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2: 2395, with C-terminally engineered cysteine. J Nucl Med 50:781–789CrossRefPubMedGoogle Scholar
- 16.Zielinski R, Lyakhov I, Jacobs A, Chertov O, Kramer-Marek G, Francella N, Stephen A, Fisher R, Blumenthal R, Capala J (2009) Affitoxin–a novel recombinant, HER2-specific, anti-cancer agent for targeted therapy of HER2-positive tumors. J Immunother 32:817–825 (Hagerstown, Md: 1997)CrossRefPubMedPubMedCentralGoogle Scholar
- 25.Schlatter D, Brack S, Banner DW, Batey S, Benz J, Bertschinger J, Huber W, Joseph C, Rufer AC, van der Klooster A, Weber M (2012) Generation, characterization and structural data of chymase binding proteins based on the human Fyn kinase SH3 domain. Landes Biosci 4:497–508Google Scholar
- 27.Covagen, Advanced Biopharmaceuticals. Covagen utilizes the unique versatility of Fynomers to create next generation biologic. http://www.covagen.com/index.php?id¼118. Accessed 21 Jun 2013
- 32.Lee CM, Shrieve DC, Zempolich KA, Lee RJ, Hammond E, Handrahan DL, Gaffney DK (2005) Correlation between human epidermal growth factor receptor family (EGFR, HER2, HER3, HER4), phosphorylated Akt (P-Akt), and clinical outcomes after radiation therapy in carcinoma of the cervix. Gynecol Oncol 99:415–421CrossRefPubMedGoogle Scholar
- 34.Mamluk R, Carvajal IM, Morse BA, Wong HK, Abramowitz J, Aslanian S, Lim AC, Gokemeijer J, Storek MJ, Lee J, Gosselin M (2010) Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2. Landes Biosci 2:199–208Google Scholar
- 38.Stumpp MT, Amstutz P (2007) DARPins: a true alternative to antibodies. Curr Opin Drug Discov Dev 10:153–159Google Scholar
- 39.Schweizer A, Rusert P, Berlinger L, Ruprecht CR, Mann A, Corthésy S, Turville SG, Aravantinou M, Fischer M, Robbiani M, Amstutz P (2008) CD4-specific designed ankyrin repeat proteins are novel potent HIV entry inhibitors with unique characteristics. PLoS Pathog 4:e1000109CrossRefPubMedPubMedCentralGoogle Scholar